Psychemedics Corporation Reports Third Quarter 2024 Financial Results
Psychemedics (NASDAQ: PMD), a leading provider of hair testing for drugs of abuse, announced its financial results for Q3 2024, ending September 30. The company's revenue for Q3 2024 was $5.2 million, a 9% decrease from $5.7 million in Q3 2023. Net loss for the quarter was $0.5 million, or $0.09 per share, compared to a net loss of $2.1 million, or $0.36 per share, in the same period last year.
For the nine months ending September 30, 2024, revenue was $15.3 million, down 11% from $17.1 million in the same period in 2023. Net loss for the nine months was $2.1 million, or $0.35 per share, compared to a net loss of $3.2 million, or $0.56 per share, for the same period last year.
Psychemedics (NASDAQ: PMD), un fornitore leader di test sui capelli per l'uso di droghe, ha annunciato i risultati finanziari per il terzo trimestre del 2024, chiuso il 30 settembre. I ricavi del terzo trimestre del 2024 sono stati di 5,2 milioni di dollari, con una diminuzione del 9% rispetto ai 5,7 milioni di dollari del terzo trimestre del 2023. La perdita netta per il trimestre è stata di 0,5 milioni di dollari, cioè 0,09 dollari per azione, rispetto a una perdita netta di 2,1 milioni di dollari, ovvero 0,36 dollari per azione, nello stesso periodo dell'anno scorso.
Per i nove mesi terminati il 30 settembre 2024, i ricavi sono stati di 15,3 milioni di dollari, in calo dell'11% rispetto ai 17,1 milioni di dollari nello stesso periodo del 2023. La perdita netta per i nove mesi è stata di 2,1 milioni di dollari, cioè 0,35 dollari per azione, rispetto a una perdita netta di 3,2 milioni di dollari, ovvero 0,56 dollari per azione, per lo stesso periodo dell'anno scorso.
Psychemedics (NASDAQ: PMD), un proveedor líder de pruebas de cabello para el consumo de drogas, anunció sus resultados financieros para el tercer trimestre de 2024, que finalizó el 30 de septiembre. Los ingresos para el tercer trimestre de 2024 fueron de 5.2 millones de dólares, una disminución del 9% desde los 5.7 millones de dólares en el tercer trimestre de 2023. La pérdida neta para el trimestre fue de 0.5 millones de dólares, o 0.09 dólares por acción, en comparación con una pérdida neta de 2.1 millones de dólares, o 0.36 dólares por acción, en el mismo período del año pasado.
Para los nueve meses que finalizaron el 30 de septiembre de 2024, los ingresos fueron de 15.3 millones de dólares, una caída del 11% desde los 17.1 millones de dólares en el mismo período de 2023. La pérdida neta para los nueve meses fue de 2.1 millones de dólares, o 0.35 dólares por acción, en comparación con una pérdida neta de 3.2 millones de dólares, o 0.56 dólares por acción, para el mismo período del año pasado.
Psychemedics (NASDAQ: PMD)는 마약 사용을 위한 모발 검사의 우수한 제공업체로, 2024년 3분기(9월 30일 종료)의 재무 결과를 발표했습니다. 2024년 3분기 매출은 520만 달러로, 2023년 3분기의 570만 달러에서 9% 감소했습니다. 이번 분기의 순손실은 50만 달러, 주당 0.09달러였으며, 지난해 같은 기간의 순손실 210만 달러, 주당 0.36달러와 비교됩니다.
2024년 9월 30일로 종료된 9개월 동안의 매출은 1530만 달러로, 2023년 같은 기간의 1710만 달러에서 11% 감소했습니다. 9개월 동안의 순손실은 210만 달러, 주당 0.35달러였으며, 지난해 같은 기간의 순손실 320만 달러, 주당 0.56달러와 비교됩니다.
Psychemedics (NASDAQ: PMD), un fournisseur leader de tests capillaires pour la détection de drogues, a annoncé ses résultats financiers pour le troisième trimestre 2024, se terminant le 30 septembre. Le chiffre d'affaires pour le troisième trimestre 2024 s'est élevé à 5,2 millions de dollars, soit une baisse de 9 % par rapport à 5,7 millions de dollars au troisième trimestre 2023. La perte nette pour le trimestre était de 0,5 million de dollars, soit 0,09 dollar par action, contre une perte nette de 2,1 millions de dollars, soit 0,36 dollar par action, pendant la même période l'année dernière.
Pour les neuf mois se terminant le 30 septembre 2024, le chiffre d'affaires était de 15,3 millions de dollars, en baisse de 11 % par rapport à 17,1 millions de dollars au cours de la même période en 2023. La perte nette pour les neuf mois était de 2,1 millions de dollars, soit 0,35 dollar par action, par rapport à une perte nette de 3,2 millions de dollars, soit 0,56 dollar par action, pour la même période l'année dernière.
Psychemedics (NASDAQ: PMD), ein führender Anbieter von Haartests auf Drogenmissbrauch, hat seine finanziellen Ergebnisse für das dritte Quartal 2024 bekannt gegeben, das am 30. September endete. Der Umsatz für das dritte Quartal 2024 betrug 5,2 Millionen Dollar, was einem Rückgang von 9% im Vergleich zu 5,7 Millionen Dollar im dritten Quartal 2023 entspricht. Der Nettverlust für das Quartal betrug 0,5 Millionen Dollar oder 0,09 Dollar pro Aktie, verglichen mit einem Nettverlust von 2,1 Millionen Dollar oder 0,36 Dollar pro Aktie im gleichen Zeitraum des Vorjahres.
Für die neun Monate bis zum 30. September 2024 betrug der Umsatz 15,3 Millionen Dollar, ein Rückgang von 11% gegenüber 17,1 Millionen Dollar im gleichen Zeitraum 2023. Der Nettverlust für die neun Monate betrug 2,1 Millionen Dollar oder 0,35 Dollar pro Aktie, verglichen mit einem Nettverlust von 3,2 Millionen Dollar oder 0,56 Dollar pro Aktie für denselben Zeitraum des Vorjahres.
- Net loss decreased to $0.5 million in Q3 2024 from $2.1 million in Q3 2023.
- Net loss for nine months decreased to $2.1 million from $3.2 million year-over-year.
- Revenue decreased by 9% to $5.2 million in Q3 2024 compared to Q3 2023.
- Revenue for the nine months decreased by 11% to $15.3 million compared to the same period in 2023.
DALLAS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ending September 30, 2024.
The Company’s revenue for three months ended September 30, 2024, was
The Company’s revenue for nine months ended September 30, 2024, was
About Psychemedics Corporation
Psychemedics Corporation is the world’s leading provider of hair testing for the detection of drugs of abuse. The Company’s patented process is used by thousands of U.S. and international clients, including Fortune 500 companies, for pre-employment and random drug testing. Major police departments, Federal Reserve banks, schools, and other public entities also rely on our unique patented drug testing process. We strongly believe our drug testing method to be superior to any other product currently in use, including traditional urine testing and other hair testing methods. To learn more, visit www.psychemedics.com.
Psychemedics Investor Contact:
Daniella Mehalik
VP of Finance
(800) 628-8073
DaniellaM@psychemedics.com
FAQ
What were Psychemedics 's Q3 2024 financial results?
How did Psychemedics 's Q3 2024 revenue compare to Q3 2023?
What was the net loss for Psychemedics in Q3 2024?
How did Psychemedics 's nine-month revenue for 2024 compare to 2023?
What was Psychemedics 's net loss for the first nine months of 2024?
